THE MCMANUS GROUP

Lobbying for ARDELYX · BioPharma Company

Filing Registration

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Mar 17, 2025

Money reported

None

Registrations and no-activity reports carry no figure.

Client based in

Massachusetts

Lobbying activity 1

Health Issues

Payment for drugs for patients with end stage renal disease

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.